[Federal Register Volume 85, Number 168 (Friday, August 28, 2020)]
[Notices]
[Page 53401]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-18979]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Medical CBRN Defense Consortium

    Notice is hereby given that, on July 30, 2020, pursuant to Section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), Medical CBRN Defense Consortium 
(``MCDC'') has filed written notifications simultaneously with the 
Attorney General and the Federal Trade Commission disclosing changes in 
its membership. The notifications were filed for the purpose of 
extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances. 
Specifically, Abiogenix, Inc.; Rochester, MI; ANP Technologies, Inc.; 
Newark, DE; Arcturus UAV, Inc.; Petaluma, CA; AstraZeneca 
Pharmaceuticals, LP; Gaithersburg, MD; Blade Therapeutics, Inc.; South 
San Francisco, CA; Celularity, Inc.; New York, NY; Commonwealth Trading 
Partners, Inc.; Alexandria, VA; Cytonus Therapeutics, Inc.; Columbus, 
OH; D. Wheatley Enterprises, Inc.; Belcamp, MD; ElectroNucleics, Inc.; 
Placentia, CA; Fast-Track Drugs & Biologics, LLC; Poolesville, MD; Fry 
Laboratories, LLC; Scottsdale, AZ; Full Effect Biotech, Inc.; Kansas 
City, KS; GAP Solutions, Inc.; Herndon, VA; iBio CDMO LLC; Bryan, TX; 
iBio, Inc.; New York, NY; Massachusetts Eye and Ear Infirmary; Boston, 
MA; MicroHealth LLC; Vienna, VA; Novavax, Inc.; Gaithersburg, MD; 
Pfizer, Inc.; New York, NY; Planet Biotechnology, Inc.; Hayward, CA; 
Primmune Therapeutics, Inc.; San Diego, CA; Quantum Leap Healthcare 
Collaborative; San Francisco, CA; QuickSilver Analytics, Inc.; 
Hampstead, NC; Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; Resonant 
Sensors, Inc.; Arlington, TX; Rubix Strategies LLC; Lawrence, MA; Shift 
Labs, Inc.; Seattle, WA; SiO2 Medical Products, Inc.; Auburn, AL; Space 
Information Laboratories; Santa Maria, CA; Teledyne Brown Engineering, 
Inc.; Huntsville, AL; TensorX Inc.; Vienna, VA; Tunnell Consulting, 
Inc.; Bethesda, MD; Ultimaxx Health, Inc.; Boca Raton, FL; University 
of Delaware on behalf of NIIMBL; Newark, DE; University of Louisville; 
Louisville, KY; Vaxart, Inc.; South San Francisco, CA; Zeteo Biomedical 
LLC; Austin, TX have been added as parties to this venture.
    Also, Onyx Government Services; Centreville, VA; Space Information 
Laboratories; Santa Maria, CA, Valaria Technical Consultants, LLC; 
Westminister, MD have withdrawn from this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and MCDC intends to file additional 
written notifications disclosing all changes in membership.
    On November 13, 2015, MCDC filed its original notification pursuant 
to Section 6(a) of the Act. The Department of Justice published a 
notice in the Federal Register pursuant to Section 6(b) of the Act on 
January 6, 2016 (81 FR 513).
    The last notification was filed with the Department on April 30, 
2020. A notice was published in the Federal Register pursuant to 
Section 6(b) of the Act on May 19, 2020 (85 FR 29976).

Suzanne Morris,
Chief, Premerger and Division Statistics, Antitrust Division.
[FR Doc. 2020-18979 Filed 8-27-20; 8:45 am]
BILLING CODE P